This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

William Regelson, MD

JAMA. 1980;243(4):337-339.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

IN BOTH randomized double-blind and nonrandomized studies, our group and others have tested hydrazine sulfate in advanced-stage cancer patients and found it to have little value.^1-4 If our clinical impressions are true, why does publicity engendered by Penthouse magazine, Gold,⁵ and Russian reports^6-8 as to hydrazine's value contradict our experience?

I first heard of hydrazine from Joseph Gold, MD, of the Syracuse Cancer Research Institute in the spring of 1973. To his credit, the use of hydrazine was based on his original concept that the glycolysis of cancer cells and the presence of cancer stimulated gluconeogenesis, which constituted a systemic metabolic circuit capable of drawing substantial amounts of energy from the cancer host.^9-10 Dr Gold postulated that this mechanism of energy loss was responsible for cancer cachexia, which he believed could be reversed by metabolically interrupting gluconeogenesis. Based on Gold's^11,12 concept that he could reverse . . . [Full Text PDF of this Article]

Author Affiliations
Medical College of Virginia Virginia Commonwealth University Richmond

From the Department of Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond.

Footnotes
Reprint requests to Department of Medicine, Medical College of Virginia, Virginia Commonwealth University, PO Box 273, Richmond, VA 23298 (Dr Regelson).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?